000			a
999			_c20228 _d20228
003			OSt
005			20231202110818.0
008			231202b xxu||||| |||| 00| 0 eng d
040			_aAIKTC-KRRC _cAIKTC-KRRC
100			_922277 _aJihad, Marwan Imad
245			_aSynthesis, characterization, and antiproliferative evaluation of novel sorafenib analogs for the treatment of hepatocellular carcinoma
250			_aVol.14(3), Jul-Sep
260			_aMumbai _bWolter Kluwer _c2023
300			_a274-279p.
520			_aCancer is a disease triggered by an uncontrolled proliferation of a cluster of cells, typically originating from a single cell. Sorafenib, a widely utilized pharmaceutical, has limitations in clinical use due to pharmacokinetic challenges and the development of resistance mechanisms. This investigation aimed to synthesize new sorafenib analogs and evaluated their activity against HepG2 cell lines, specifically targeting hepatocellular carcinoma (HCC). Seven sorafenib analogs were synthesized and identified by Fourier-transform infrared spectroscopy and 1H-NMR spectra. Cytotoxicity of the analogs was assessed on the human HepG2 cancer cell line by (3-(4, 5-dimethylthazolk-2-yl)-2, 5-diphenyl tetrazolium bromide) colorimetric assay. Results revealed that among the studied compounds, 4b exhibited the most pronounced cytotoxicity against cancer cells, surpassing even the efficacy of sorafenib. This suggested that small substitutions on the NH moiety play a crucial role in the activity against the human HepG2 liver cancer cell line. These findings provide valuable insights for the development of potential anticancer-targeting HCC.
650		0	_94639 _aPHARMACEUTICS
700			_922248 _aMahdi, Monther Faisal
773	0		_tJournal of advanced pharmaceutical technology and research _x2231-4040
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483918/ _yClick here
942			_2ddc _cAR